When does outsourcing your regulatory affairs function actually make sense?
There is a question most pharmaceutical businesses face at some point.
Build an in-house regulatory affairs function, or bring in external expertise?
It looks like a resourcing decision. In practice, it is a strategic one.
Get it wrong and you either carry overhead you cannot justify, or you find yourself under-resourced at precisely the moment that counts. This article sets out how to think it through.
The case for in-house RA
An internal regulatory affairs function makes clear sense when the work is continuous, high-volume, and deeply embedded in how the business operates.
If you are running a marketed portfolio across multiple markets, managing a year-round submissions programme, or working in a segment where regulatory intelligence needs to feed into commercial decisions daily, dedicated in-house resource is rational. The cost is justified by the volume and the value.
In-house teams also build institutional knowledge over time. They know your products, your history with regulators, your internal systems, and the context behind every decision. That continuity has genuine value.
When in-house RA is the right call
Your regulatory workload is ongoing, not episodic
You are managing a broad marketed portfolio across multiple regions
Regulatory intelligence needs to flow directly into daily commercial decisions
Continuity and institutional knowledge are critical competitive advantages
Where in-house RA runs into trouble
The problem is that regulatory workload is rarely flat.
Most businesses experience significant peaks driven by submissions, inspections, product launches, remediation programmes, or market expansions, followed by periods where a full team is underutilised. Hiring to peak demand is expensive and difficult to unwind. Hiring to base demand leaves you exposed when it matters most.
There is also a skills dimension that is often underestimated. Regulatory affairs is not one discipline. Submissions strategy, CMC, pharmacovigilance, labelling, market access, and regional regulatory intelligence each require different expertise. A small in-house team cannot credibly cover all of it.
The moments when you need specialist knowledge are usually the moments you cannot afford to get it wrong.
The peak/base trap
Hiring to peak demand: high fixed cost, hard to unwind when the workload drops
Hiring to base demand: under-resourced when a submission, inspection, or remediation hits
Neither position is comfortable. Outsourcing offers a third option: right-sized expertise, available when the work demands it
Five situations where outsourcing makes the stronger case
1. You are scaling into new markets
Regulatory requirements vary significantly by market. If you are entering the EU, the US, or any emerging market for the first time, you need people who already understand those systems, those relationships, and the practical realities of submission timelines.
Hiring that capability from scratch takes time you may not have. A well-structured outsourcing engagement gives you immediate access to the right expertise.
2. You have a defined project with a clear endpoint
If you are managing a specific submission, responding to a regulatory query, or working through post-inspection remediation, the work has a beginning and an end. Bringing in external resource for a defined scope is almost always more efficient than hiring for it, and avoids the overhead of restructuring when the project closes.
3. Your internal team has a capability gap
Even well-resourced RA functions encounter areas outside their direct experience. A CMC question on a novel formulation, a complex variation strategy, or a Type II variation for a new indication may require expertise your team does not hold.
Outsourcing that component, while keeping your internal team in control of the broader programme, is a practical and widely used approach.
4. You are pre-commercial or early-stage
For biotech and emerging pharma companies, building a full in-house RA team before you have revenue from a marketed product is difficult to justify. Outsourcing gives you senior regulatory expertise at the point you need it, without committing to the fixed cost of a team that your current stage cannot support.
5. You need to move faster than hiring allows
Regulatory timelines do not wait for recruitment processes. Hiring senior regulatory talent takes three to six months in most markets. A well-structured outsourcing engagement can be operational within days.
When speed matters, outsourcing is often the only realistic option.
Need regulatory affairs support now?
TDP provides outsourced RA capability across the full product lifecycle. Whether you need a senior regulatory lead for a specific submission or a team to cover a market expansion, we can be operational quickly.
Speak to us about your situation before it becomes time-critical.
What most mature businesses actually do
The in-house versus outsourced framing is rarely how it plays out in practice.
Most businesses with genuine regulatory complexity operate a hybrid model. A core in-house function, typically at director or VP level, holds strategic oversight, manages regulator relationships, and maintains institutional knowledge. External resource is brought in for volume, specialist areas, peak periods, or defined projects.
This gives you the continuity of an internal function with the scalability and breadth of expertise that outsourcing provides.
Done well, the external team operates as a seamless extension of your internal capability, not a separate supplier relationship.
What to look for in an outsourced RA partner
The quality of the partner matters as much as the decision to outsource. You are extending your regulatory capability. The people you bring in will represent your organisation to regulators and internal stakeholders alike.
Questions worth asking before you engage
Do they have genuine experience in your therapy area, product type, and target markets?
Can they provide named individuals with verifiable regulatory track records, not anonymous resource pools?
Do they understand your business objectives, or are they focused purely on regulatory mechanics?
Can they work embedded within your team, or do they operate at arm's length?
What is their approach when the regulatory path is unclear or contested?
The last question matters more than most. Regulatory affairs is rarely straightforward. The value of a strong external partner is not just technical knowledge. It is sound judgement under uncertainty, and the confidence to give you a direct view on risk and strategy, even when the answer is not what you were hoping for.
Making the decision
There is no universal right answer on in-house versus outsourced regulatory affairs.
If your regulatory challenges are specific, time-bounded, or outside your current capability, outsourcing is likely the faster and more cost-effective route. If your workload is continuous, high-volume, and strategically embedded, building in-house makes sense. For most businesses, the right answer sits somewhere in between.
The question worth asking is not which model is better in theory. It is which model is better for your business, at this stage, given the work that actually needs doing.
If you are working through that question, we are happy to give you a direct view.
Speak to TDP about outsourced regulatory affairs
TDP provides outsourced regulatory affairs support to pharmaceutical and life sciences businesses across the full product lifecycle.
Whether you need a senior regulatory lead to drive a specific submission, a team to extend your existing function, or strategic oversight during a complex programme, we work as an integrated part of your operation. Not a supplier at a distance.